Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Learn more about:
Related Clinical Trial
Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
The Effect and Safety of Tocilizumab Treatment on IRPF
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
Treatment of IgG4-Related Disease With Revlimid and Rituximab
National Registry of IRPF in China
A Prospective Cohort Study of IRPF in China
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria